The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DVA | -20.89% | +41.77% | +7.23% | +3,068% |
| S&P | +14.5% | +93.32% | +14.09% | +1,052% |
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
The Oracle of Omaha's investing strategies have stood the test of time.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.38B | 6.1% |
| Gross Profit | $943.28M | 8.6% |
| Gross Margin | 27.91% | 0.6% |
| Market Cap | $10.75B | -11.5% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 76K | 8.6% |
| Net Income | $275.22M | -8.2% |
| EBITDA | $705.18M | 4.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $796.96M | 58.4% |
| Accounts Receivable | $2.44B | 6.0% |
| Inventory | 146.3 | 15.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.20B | 13.7% |
| Short Term Debt | $611.69M | -35.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.85% | -0.2% |
| Return On Invested Capital | 6.64% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $203.30M | -70.0% |
| Operating Free Cash Flow | $324.39M | -59.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.67 | 13.92 | 15.14 | 14.00 | -5.08% |
| Price to Book | 23.27 | 31.95 | 101.71 | -41.21 | -414.03% |
| Price to Sales | 1.11 | 0.98 | 0.96 | 0.84 | -14.92% |
| Price to Tangible Book Value | -2.18 | -1.76 | -1.65 | -1.40 | -25.30% |
| Price to Free Cash Flow TTM | 9.88 | 8.51 | 7.05 | 8.54 | -11.37% |
| Enterprise Value to EBITDA | 37.48 | 39.17 | 42.77 | 35.35 | -5.34% |
| Free Cash Flow Yield | 10.1% | 11.7% | 14.2% | 11.7% | 12.83% |
| Return on Equity | 104.4% | 159.1% | 260.9% | 635.3% | 509.84% |
| Total Debt | $12.20B | $12.07B | $12.32B | $12.82B | 9.76% |
DVA earnings call for the period ending December 31, 2024.
DVA earnings call for the period ending September 30, 2024.
DVA earnings call for the period ending June 30, 2024.
DVA earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
